Literature DB >> 27698189

miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

Ying Zhou1, Jason Dang2, Kung-Yen Chang2, Edwin Yau3, Pedro Aza-Blanc1, Jorge Moscat4, Tariq M Rana5.   

Abstract

Global miRNA functional screens can offer a strategy to identify synthetic lethal interactions in cancer cells that might be exploited therapeutically. In this study, we applied this strategy to identify novel gene interactions in KRAS-mutant cancer cells. In this manner, we discovered miR-1298, a novel miRNA that inhibited the growth of KRAS-driven cells both in vitro and in vivo Using miR-TRAP affinity purification technology, we identified the tyrosine kinase FAK and the laminin subunit LAMB3 as functional targets of miR-1298. Silencing of FAK or LAMB3 recapitulated the synthetic lethal effects of miR-1298 expression in KRAS-driven cancer cells, whereas coexpression of both proteins was critical to rescue miR-1298-induced cell death. Expression of LAMB3 but not FAK was upregulated by mutant KRAS. In clinical specimens, elevated LAMB3 expression correlated with poorer survival in lung cancer patients with an oncogenic KRAS gene signature, suggesting a novel candidate biomarker in this disease setting. Our results define a novel regulatory pathway in KRAS-driven cancers, which offers a potential therapeutic target for their eradication. Cancer Res; 76(19); 5777-87. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27698189      PMCID: PMC5155639          DOI: 10.1158/0008-5472.CAN-15-2936

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

2.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

3.  The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Authors:  Madhu S Kumar; David C Hancock; Miriam Molina-Arcas; Michael Steckel; Phillip East; Markus Diefenbacher; Elena Armenteros-Monterroso; François Lassailly; Nik Matthews; Emma Nye; Gordon Stamp; Axel Behrens; Julian Downward
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

4.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

Review 6.  Tumour microenvironment: laminin 332 in squamous-cell carcinoma.

Authors:  M Peter Marinkovich
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

7.  RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

Authors:  Georgia Konstantinidou; Giorgio Ramadori; Francesca Torti; Kim Kangasniemi; Rachel E Ramirez; Yiran Cai; Carmen Behrens; Michael T Dellinger; Rolf A Brekken; Ignacio I Wistuba; Adriana Heguy; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Discov       Date:  2013-01-28       Impact factor: 39.397

8.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

9.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Authors:  Michael Steckel; Miriam Molina-Arcas; Britta Weigelt; Michaela Marani; Patricia H Warne; Hanna Kuznetsov; Gavin Kelly; Becky Saunders; Michael Howell; Julian Downward; David C Hancock
Journal:  Cell Res       Date:  2012-05-22       Impact factor: 25.617

10.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

View more
  27 in total

1.  miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway.

Authors:  Yuki Takagawa; Yasuyuki Gen; Tomoki Muramatsu; Kousuke Tanimoto; Jun Inoue; Hiroyuki Harada; Johji Inazawa
Journal:  Mol Ther       Date:  2020-04-11       Impact factor: 11.454

2.  All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS.

Authors:  Adrian Vallejo; Karmele Valencia; Silvestre Vicent
Journal:  Mol Cell Oncol       Date:  2017-04-05

3.  Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.

Authors:  Edwin H Yau; Indrasena Reddy Kummetha; Gianluigi Lichinchi; Rachel Tang; Yunlin Zhang; Tariq M Rana
Journal:  Cancer Res       Date:  2017-09-27       Impact factor: 12.701

4.  Laminin 332 expression and prognosis in breast cancer.

Authors:  Philip M Carpenter; Argyrios Ziogas; Emma M Markham; Alegria S Cantillep; Rui Yan; Hoda Anton-Culver
Journal:  Hum Pathol       Date:  2018-08-17       Impact factor: 3.466

5.  Inhibition of miR-1298-5p attenuates sepsis lung injury by targeting SOCS6.

Authors:  Jian Ma; Li-Yun Xu; Qiu-Hong Sun; Xiao-Yu Wan
Journal:  Mol Cell Biochem       Date:  2021-06-07       Impact factor: 3.396

6.  LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer.

Authors:  Zhehui Zhu; Jinglue Song; Yuegui Guo; Zhenyu Huang; Xiaojian Chen; Xuening Dang; Yuji Huang; Yuhan Wang; Weijun Ou; Yili Yang; Wei Yu; Chen-Ying Liu; Long Cui
Journal:  Oncogene       Date:  2020-05-12       Impact factor: 9.867

7.  Genome-wide miRNA response to anacardic acid in breast cancer cells.

Authors:  David J Schultz; Penn Muluhngwi; Negin Alizadeh-Rad; Madelyn A Green; Eric C Rouchka; Sabine J Waigel; Carolyn M Klinge
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

Review 8.  Further the liquid biopsy: Gathering pieces of the puzzle of genometastasis theory.

Authors:  Ana García-Casas; Dolores C García-Olmo; Damián García-Olmo
Journal:  World J Clin Oncol       Date:  2017-10-10

Review 9.  KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.

Authors:  Marta Román; Iosune Baraibar; Inés López; Ernest Nadal; Christian Rolfo; Silvestre Vicent; Ignacio Gil-Bazo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 41.444

Review 10.  Molecular genetics and cellular events of K-Ras-driven tumorigenesis.

Authors:  G G Jinesh; V Sambandam; S Vijayaraghavan; K Balaji; S Mukherjee
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.